These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8689509)

  • 1. Pharmacokinetics and antitumor effects of an interleukin-2 immunocomplexing agent in murine renal cell carcinoma.
    Oya M; Marumo K; Murai M; Tazaki H
    Int J Urol; 1996 Mar; 3(2):141-4. PubMed ID: 8689509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
    Marumo K; Oya M; Murai M; Tazaki H
    Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
    Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
    J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
    Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
    BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
    Wigginton JM; Komschlies KL; Back TC; Franco JL; Brunda MJ; Wiltrout RH
    J Natl Cancer Inst; 1996 Jan; 88(1):38-43. PubMed ID: 8847724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-tumor effect of IL-2 and hemin on murine renal cell carcinoma].
    Tsuji A
    Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):604-10. PubMed ID: 8189658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
    Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
    Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
    Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR
    Cancer Invest; 1991; 9(1):35-48. PubMed ID: 2012995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects and pharmacological interaction of xiao-chai-hu-tang (sho-saiko-to) and interleukin 2 in murine renal cell carcinoma.
    Huang Y; Marumo K; Murai M
    Keio J Med; 1997 Sep; 46(3):132-7. PubMed ID: 9339641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of interleukin-2 entrapped in liposomes on murine renal cell carcinoma.
    Oya M
    Keio J Med; 1994 Mar; 43(1):37-44. PubMed ID: 8189679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.